IDH1 and acute myeloid leukemia: One such genomic target leading to recent FDA approvals in AML is mutated IDH1 R132 (isocitrate dehydrogenase 1), which plays a role in tumorigenesis through its involvement in the dysregulation of DNA methylation, metabolism, and other cellular functions [2, 3].